A Narrative Review of Therapeutic Peripheral Nerve Blocks for Chronic Orofacial Pain Conditions

Aims: To provide an analysis of the different therapeutic peripheral nerve blocks (PNBs), as well as their limitations and the related evidence base for their use in chronic orofacial pain (OFP) conditions, excluding migraine and other headache conditions. Methods/results: The evidence base for therapeutic PNBs for chronic OFP is poor and highlights the need for improved research in this area. The diagnostic criteria and interventional PNB definitions and techniques varied between studies. In addition, the placebo effect of a peripheral injection and its resultant bias was rarely considered. Most of the PNB interventions for temporomandibular disorders were for arthrogenous disorders (arthritis and disc entrapment with pain). However, there is emerging evidence for the use of onabotulinum toxin (BTX-A) in trigeminal neuralgia, with four prospective randomized controlled trials (pRCTs), and for postherpetic neuralgia. However, despite high-level evidence for BTX-A in posttraumatic neuropathic pain outside the trigeminal system, there is no evidence for its use for PTNP within the trigeminal system. Conclusion: There may be emerging evidence for treating trigeminal neuralgia with BTX-A injections; however, there is a need for future clinical studies of therapeutic PNBs in orofacial pain conditions.

reversible peripheral nerve block; therapeutic nerve block; therapeutic nerve injections; trigeminal nerve block; trigeminal nerve injections

1. Zakrzewska J, Buchanan JA. Burning mouth syndrome. BMJ Clin Evid 2016;2016:1301.

2. International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia 2020;40:129–221.

3. Fischoff D, Spivakovsky S. Are pharmacological treatments for orofacial pain effective? Evid Based Dent 2018;19:28–29.

4. Romero-Reyes M, Uyanik JM. Orofacial pain management: Current perspectives. J Pain Res 2014;7:99–115.

5. Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012;11:CD007407.

6. Nova CV, Zakrzewska JM, Baker SR, Riordain RN. Treatment outcomes in trigeminal neuralgia-a systematic review of domains, dimensions and measures. World Neurosurg X 2020;6:100070.

7. Zuniga JR, Renton TF. Managing post-traumatic trigeminal neuropathic pain: Is surgery enough? J Neurol Neuromedicine 2016;1:10–14.

8. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers 2017;3:17002.

9. Attal N, de Andrade DC, Adam F, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neu-ropathic pain (BOTNEP): A randomised, double-blind, place-bo-controlled trial. Lancet Neurol 2016;15:555–565.

10. Heesen M, Klimek M, Imberger G, Hoeks SE, Rossaint R, Straube S. Co-administration of dexamethasone with periph-eral nerve block: Intravenous vs perineural application: system-atic review, meta-analysis, meta-regression and trial-sequential analysis. Br J Anaesth 2018;120:212–227.

11. Oh HM, Chung ME. Botulinum toxin for neuropathic pain: A review of the literature. Toxins (Basel) 2015;7:3127–3154.

12. Nader A, Kendall MC, De Oliveria GS, et al. Ultrasound-guided trigeminal nerve block via the pterygopalatine fossa: An effective treatment for trigeminal neuralgia and atypical facial pain. Pain Physician 2013;16:e537–e545.

13. Hogan QH, Abram SE. Neural blockade for diagnosis and prognosis. A review. Anesthesiology 1997;86:216–241.

14. Jiménez-Almonte JH, Wyles CC, Wyles SP, et al. Is local infiltration analgesia superior to peripheral nerve blockade for pain management after THA: A network meta-analysis. Clin Orthop Relat Res 2016;474:495–516.

15. Anugerah A, Nguyen K, Nader A. Technical considerations for approaches to the ultrasound-guided maxillary nerve block via the pterygopalatine fossa: A literature review. Reg Anesth Pain Med 2020;45:301–305.

16. Shauly O, Gould DJ, Sahai-Srivastava S, Patel KM. Greater occipital nerve block for the treatment of chronic migraine headaches: A systematic review and meta-analysis. Plast Reconstr Surg 2019;144:943–952.

17. Ashkenazi A, Blumenfeld A, Napchan U, et al. Peripheral nerve blocks and trigger point injections in headache management- a systematic review and suggestions for future research. Headache 2010;50:943–952.

18. Kinfe TM, Schuss P, Vatter H. Occipital nerve block prior to occipital nerve stimulation for refractory chronic migraine and chronic cluster headache: Myth or prediction? Cephalalgia 2015;35:359–362.

19. Kleen JK, Levin M. Injection therapy for headache and facial pain. Oral Maxillofac Surg Clin North Am 2016;28:423–434.

20. Al-Moraissi EA, Wolford LM, Ellis E 3rd, Neff A. The hierarchy of different treatments for arthrogenous temporomandibular disorders: A network meta-analysis of randomized clinical trials. J Craniomaxillofac Surg 2020;48:9–23.

21. DuPont JS Jr. Simplified anesthesia blocking of the temporo-mandibular joint. Gen Dent 2004;52:318–320.

22. Quek SY, Subramanian G, Patel J, Ananthan S, Zagury JG, Khan J. Efficacy of regional nerve block in management of myofascial pain of masseteric origin. Cranio 2015;33:285–290.

23. Young AL, Khan J, Thomas DC, Quek SY. Use of masseteric and deep temporal nerve blocks for reduction of mandibular dislocation. Anesth Prog 2009;56:9–13.

24. Fine PG, Milano R, Hare BD. The effects of myofascial trigger point injections are naloxone reversible. Pain 1988;32:15–20.

25. Nitecka-Buchta A, Walczynska-Dragon K, Batko-Kapustecka J, Wieckiewicz M. Comparison between collagen and lidocaine intramuscular injections in terms of their efficiency in decreasing myofascial pain within masseter muscles: A randomized, single-blind controlled trial. Pain Res Manag 2018;2018:8261090.

26. Ayesh EE, Ernberg M, Svensson P. Effects of local anesthetics on somatosensory function in the temporomandibular joint area. Exp Brain Res 2007;180:715–725.

27. Toller PA. Use and misuse of intra-articular corticosteroids in treatment of temporomandibular joint pain. Proc R Soc Med 1977;70:461–463.

28. Wenneberg B, Kopp S, Gröndahl HG. Long-term effect of in-tra-articular injections of a glucocorticosteroid into the TMJ: A clinical and radiographic 8-year follow-up. J Craniomandib Disord 1991;5:11–18.

29. Torres D, Zaror C, Iturriaga V, Tobias A. Intra-articular corticosteroids for treatment of temporomandibular joint internal disorders: Protocol for systematic review and network me-ta-analysis. BMJ Open 2020;10:e034327.

30. Kopp S, Akerman S, Nilner M. Short-term effects of intra-ar-ticular sodium hyaluronate, glucocorticoid, and saline injections on rheumatoid arthritis of the temporomandibular joint. J Craniomandib Disord 1991;5:231–238.

31. Samiee A, Sabzerou D, Edalatpajouh F, Clark GT, Ram S. Temporomandibular joint injection with corticosteroid and local anesthetic for limited mouth opening. J Oral Sci 2011;53:321–325.

32. Stoll ML, Good J, Sharpe T, et al. Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. J Oral Maxillofac Surg 2012;70:1802–1807.

33. Shi Z, Guo C, Awad M. Hyaluronate for temporomandibular joint disorders. Cochrane Database Syst Rev 2003:CD002970.

34. Manfredini D, Guarda-Nardini L, Winocur E, Piccotti F, Ahlberg J, Lobbezoo F. Research diagnostic criteria for temporoman-dibular disorders: A systematic review of axis I epidemiologic findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:453–462.

35. Machado E, Bonotto D, Cunali PA. Intra-articular injections with corticosteroids and sodium hyaluronate for treating temporomandibular joint disorders: A systematic review. Dental Press J Orthod 2013;18:128–133.

36. Moldez MA, Camones VR, Ramos GE, Padilla M, Enciso R. Effectiveness of intra-articular injections of sodium hyaluronate or corticosteroids for intracapsular temporomandibular disorders: A systematic review and meta-analysis. J Oral Facial Pain Headache 2018;32:53–66.

37. Liu Y, Wu J, Fei W, et al. Is there a difference in intra-artic-ular injections of corticosteroids, hyaluronate, or placebo for temporomandibular osteoarthritis? J Oral Maxillofac Surg 2018;76:504–514.

38. Bousnaki M, Bakopoulou A, Koidis P. Platelet-rich plasma for the therapeutic management of temporomandibular joint disorders: A systematic review. Int J Oral Maxillofac Surg 2018;47:188–198.

39. Moreau N, Dieb W, Descroix V, Svensson P, Ernberg M, Boucher Y. Topical review: Potential use of botulinum toxin in the management of painful posttraumatic trigeminal neuropathy. J Oral Facial Pain Headache 2017;31:7–18.

40. Wei J, Zhu X, Yang G, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav 2019;9:e01409.

41. Dach F, Éckeli ÁL, Ferreira Kdos S, Speciali JG. Nerve block for the treatment of headaches and cranial neuralgias - a practical approach. Headache 2015;55(suppl 1):59–71.

42. Jürgens TP, Müller P, Seedorf H, Regelsberger J, May A. Occipital nerve block is effective in craniofacial neuralgias but not in idiopathic persistent facial pain. J Headache Pain 2012;13:199–213.

43. Benoliel R, Kahn J, Eliav E. Peripheral painful traumatic trigeminal neuropathies. Oral Dis 2012;18:317–332.

44. Gogia AR, Chandra KN. Stellate ganglion block can relieve symptoms and pain and prevent facial nerve damage. Saudi J Anaesth 2015;9:204–206.

45. Lynch ME, Elgeneidy AK. The role of sympathetic activity in neuropathic orofacial pain. J Orofac Pain 1996;10:297–305.

46. Niki Y, Kanai A, Hoshi K, Okamoto H. Immediate analgesic effect of 8% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia. Pain Med 2014;15:826–831.

47. Takechi K, Konishi A, Kikuchi K, et al. Real-time ultra-sound-guided infraorbital nerve block to treat trigeminal neuralgia using a high concentration of tetracaine dissolved in bupivacaine. Scand J Pain 2015;6:51–54.

48. Perloff MD, Chung JS. Urgent care peripheral nerve blocks for refractory trigeminal neuralgia. Am J Emerg Med 2018;36:2058–2060.

49. Di Stani F, Ojango C, Dugoni D, et al. Combination of pharmacotherapy and lidocaine analgesic block of the peripheral trigeminal branches for trigeminal neuralgia: A pilot study. Arq Neuropsiquiatr 2015;73:660–664.

50. Campbell RL. The role of nerve blocks in the diagnosis of traumatic trigeminal neuralgia. Oral Maxillofac Surg Clinics 1992;4:369–374.

51. Moore D, Chong MS, Shetty A, Zakrzewska JM. A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth 2019;123:e385–e396.

52. Yang F, Lin Q, Dong L, Gao X, Zhang S. Efficacy of 8 different drug treatments for patients with trigeminal neuralgia: A network meta-analysis. Clin J Pain 2018;34:685–690.

53. Jürgens TP, Müller P, Seedorf H, Regelsberger J, May A. Occipital nerve block is effective in craniofacial neuralgias but not in idiopathic persistent facial pain. J Headache Pain 2012;13:199–213.

54. Evans RW. Peripheral nerve blocks and trigger point injections in headache management: Trigeminal neuralgia does not respond to occipital nerve block. Headache 2010;50:1215–1216.

55. Ho KWD, Przkora R, Kumar S. Sphenopalatine ganglion: Block, radiofrequency ablation and neurostimulation - a systematic review. J Headache Pain 2017;18:118.

56. Peterson JN, Schames J, Schames M, King E. Sphenopalatine ganglion block: A safe and easy method for the management of orofacial pain. Cranio 1995;13:177–181.

57. Manahan AP, Malesker MA, Malone PM. Sphenopalatine ganglion block relieves symptoms of trigeminal neuralgia: A case report. Nebr Med J 1996;81:306–309.

58. Akbas M, Gunduz E, Sanli S, Yegin A. Sphenopalatine ganglion pulsed radiofrequency treatment in patients suffering from chronic face and head pain. Braz J Anesthesiol 2016;66:50–54.

59. Lim SM, Park HL, Moon HY, et al. Ultrasound-guided infraorbital nerve pulsed radiofrequency treatment for intractable postherpetic neuralgia —a case report. Korean J Pain 2013;26:84–88.

60. Makharita MY, Amr YM, El-Bayoumy Y. Effect of early stellate ganglion blockade for facial pain from acute herpes zoster and incidence of postherpetic neuralgia. Pain Physician 2012;15:467–474.

61. Walega DR, Smith C, Epstein JB. Bilateral stellate ganglion blockade for recalcitrant oral pain from Burning Mouth Syndrome: A case report. J Oral Facial Pain Headache 2014;28:171–175.

62. Grémeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, Woda A. Effect of lingual nerve block on burning mouth syndrome (stomatodynia): A randomized crossover trial. Pain 2010;149:27–32.

63. Kolkka-Palomaa M, Jääskeläinen SK, Laine MA, Teerijoki-Oksa T, Sandell M, Forssell H. Pathophysiology of primary burning mouth syndrome with special focus on taste dysfunction: A review. Oral Dis 2015;21:937–948.

64. Formaker BK, Mott AE, Frank ME. The effects of topical anesthesia on oral burning in burning mouth syndrome. Ann N Y Acad Sci 1998;855:776–780.

65. Häggman-Henrikson B, Alstergren P, Davidson T, et al. Pharmacological treatment of orofacial pain - health technology assessment including a systematic review with network meta-analysis. J Oral Rehabil 2017;44:800–826.

66. Gady J, Ferneini EM. Botulinum toxin A and headache treatment. Conn Med 2013;77:165–166.

67. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM; BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled ex-ploratory study. Headache 2007;47:486–499.

68. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921–936.

69. Dach F, Éckeli ÁL, Ferreira Kdos S, Speciali JG. Nerve block for the treatment of headaches and cranial neuralgias - a prac-tical approach. Headache 2015;55(suppl 1):59–71.

70. Wolff AP, Groen GJ, Wilder-Smith OH, Richardson J, van Egmond J, Crul BJ. Do diagnostic segmental nerve root blocks in chronic low back pain patients with radiation to the leg lack distinct sensory effects? A preliminary study. Br J Anaesth 2006;96:253–258.

71. Vaccarino AL, Melzack R. Temporal processes of formalin pain: Differential role of the cingulum bundle, fornix pathway and medial bulboreticular formation. Pain 1992;49:257–271.

72. Petersen GL, Finnerup NB, Nørskov KN, et al. Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain 2012;153:1292–1300.

73. Santos Lasaosa S, Cuadrado Pérez ML, Guerrero Peral AL, et al. Consensus recommendations for anaesthetic peripheral nerve block. Neurologia 2017;32:316–330.

74. Patel UK, Saleem S, Anwar A, et al. Characteristics and treatment effectiveness of the nummular headache: A systematic review and analysis of 110 cases. BMJ Neurol Open 2020;2:e000049.

75. Trautmann A, Goebeler M, Stoevesandt J. Twenty years’ experience with anaphylaxis-like reactions to local anesthetics: genuine allergy is rare. J Allergy Clin Immunol Pract 2018;6:2051–2058.e1.

76. Blumenfeld A, Ashkenazi A, Napchan U, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches–a narrative review. Headache 2013;53:437–446.

77. McMahon RE, Adams W, Spolnik KJ. Diagnostic anesthesia for referred trigeminal pain: Part 2. Compendium 1992;13:980, 983, 986, passim.